Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Before Starting Chemotherapy

• Authors: Ilana Graetz, Emory University; Puneet Chehal, Emory University; X Hu, Emory University; C Kaplan, University of Southern California; RA Krukowski, Univ Tennessee; RH Lan, Univ Tennessee; E Stepanski, ConcertAI; L Schwartzberg, West Canc Ctr & Res Inst; G Vidal, West Canc Ctr & Res Inst
• Journal Title: JAMA NETWORK OPEN
• Volume: Volume 4, Number 6
• Publisher: AMER MEDICAL ASSOC | 2021-06-01, Pages e2112076-e2112076
• Type of Work: Article
• Publisher DOI: http://doi.org/10.1001/jamanetworkopen.2021.12076
• Keywords: Science & Technology; Life Sciences & Biomedicine; Medicine, General & Internal; General & Internal Medicine; QUALITY-OF-LIFE; BLACK-WHITE DISPARITIES; AFRICAN-AMERICAN WOMEN; 50 LARGEST CITIES; ADJUVANT CHEMOTHERAPY; MEASUREMENT EQUIVALENCE; EARLY DISCONTINUATION; RACIAL-DIFFERENCES; UNITED-STATES; SURVIVAL

Abstract

Importance: Race disparities persist in breast cancer mortality rates. One factor associated with these disparities may be differences in symptom burden, which may reduce chemotherapy tolerance and increase early treatment discontinuation. Objectives: To compare symptom burden by race among women with early-stage breast cancer before starting chemotherapy and quantify symptom differences explained by baseline characteristics. Design, Setting, and Participants: A cross-sectional analysis of symptom burden differences by race among Black and White women with a diagnosis of stage I to III, hormone receptor-positive breast cancer who had a symptom report collected before chemotherapy initiation in a large cancer center in the southern region of the US from January 1, 2007, through December 31, 2015. Analyses were conducted from November 1, 2019, to March 31, 2021. Blinder-Oaxaca decomposition was used, adjusting for baseline sociodemographic and clinical characteristics. Main Outcomes and Measures: Four symptom composite scores with a mean (SD) of 50 (10) were reported before starting chemotherapy (baseline) and were derived from symptom items: general physical symptoms (11 items), treatment adverse effects (8 items), acute distress (4 items), and despair (7 items). Patients rated the severity of each symptom they experienced in the past week on a scale of 0 to 10 (where 0 indicates not a problem and 10 indicates as bad as possible). Results: A total of 1338 women (mean [SD] age, 54.6 [11.6] years; 420 Black women [31.4%] and 918 White women [68.6%]) were included in the study. Before starting chemotherapy, Black women reported a statistically significantly higher (ie, worse) symptom composite score than White women for adverse effects (44.5 vs 43.8) but a lower acute distress score (48.5 vs 51.0). Decomposition analyses showed that Black patients' characteristics were associated with higher symptom burden across all 4 scores. However, these differences were offset by relatively greater, statistically significant, unexplained physical, distress, and despair symptom reporting by White patients. Conclusions and Relevance: In this study, before starting chemotherapy, Black patients with early-stage breast cancer reported significantly higher burden for symptoms that may be exacerbated with chemotherapy and lower distress symptoms compared with White patients. Future studies should explore how symptoms change before and after treatment and differ by racial/ethnic groups and how they are associated with treatment adherence and mortality disparities..